Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 901–1,000 of 1,016
Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC)
Rysz, J., Ławiński, J., Franczyk, B., & Gluba-Brzózka, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125577 · Cited by 37
“The CheckMate 214 was a landmark phase III, multicenter, open-label study that compared the dual immune checkpoint blockade with nivolumab (anti-PD-1) and ipili-mumab (anti-CTLA-4) versus sunitinib in patients with previously untreated advanced or metastatic RCC [10].”
InfluentialMotzer, R. J., Escudier, B. J., Burotto, M., Powles, T. B., Apolo, A. B., Bourlon, M. T., Shah, A. Y., Porta, C., Suárez, C., Barrios, C. H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.09.006 · Cited by 50
Self-citationLiver Toxicity with Cancer Checkpoint Inhibitor Therapy
Nadeau, B. A., Fecher, L. A., Owens, S. R., & Razumilava, N. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1667358 · Cited by 37
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment
Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 38
“Other significant results regarding the use of the combination of ipilimumab and nivolumab were obtained in the context of advanced renalcell carcinoma when compared with the first line treatment sunitinib (NCT02231749) [60].”
ResultThe role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
Tomassetti, S., Chen, R., & Dandapani, S. V. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719841591 · Cited by 36
Chen, J., Hu, G., Chen, Z., Wan, X., Tan, C., Zeng, X., & Cheng, Z. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00820-6 · Cited by 35
“The combination of two immune checkpoint inhibitors, nivolumab and ipilimumab, was approved for the first-line treatment of patients with aRCC based on the CheckMate 214 trial [19].”
Gonnet, A., Salabert, L., Roubaud, G., Catena, V., Brouste, V., Buy, X., Goupil, M. G., Ravaud, A., & Palussière, J. (2019) · BMC Cancer · doi:10.1186/s12885-019-6345-2 · Cited by 35
Self-citationLandscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia
Maggio, I., Manuzzi, L., Lamberti, G., Ricci, A. D., Tober, N., & Campana, D. (2020) · Cancers · doi:10.3390/cancers12040832 · Cited by 36
Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Abdou, Y. G., Pandey, M. R., Sarma, M., Shah, S., Baron, J. I., & Ernstoff, M. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14316 · Cited by 36
Wu, Z., Man, S., Sun, R., Li, Z., Wu, Y., & Zuo, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106613 · Cited by 39
Su, Y.-J., Fu, J., Du, J., & Wu, B. Y. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920950199 · Cited by 35
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 38
Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy
Kuehm, L. M., Khojandi, N., Piening, A., Klevorn, L. E., Geraud, S. C., McLaughlin, N. R., Griffett, K., Burris, T. P., Pyles, K. D., Nelson, A. M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0396 · Cited by 35
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
Wood, C. G., Ferguson, J. E., Parker, J. S., Moore, D. T., Whisenant, J. G., Maygarden, S. J., Wallen, E., Kim, W. Y., Milowsky, M. I., Beckermann, K. E., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132852 · Cited by 37
“ICB has broad indications in the treatment of metastatic disease on the basis of RR and overall survival data (10).”
BackgroundSelf-citationGaucher, L., Adda, L., Séjourné, A., Joachim, C., Chaby, G., Poulet, C., Liabeuf, S., Gras‐Champel, V., Masmoudi, K., Moreira, A., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921996656 · Cited by 42
Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
Schoenhals, J. E., Mohamad, O., Christie, A. L., Zhang, Y., Li, D., Singla, N., Bowman, I. A., Arafat, W., Hammers, H. J., Courtney, K. D., et al. (2021) · Advances in Radiation Oncology · doi:10.1016/j.adro.2021.100692 · Cited by 38
Self-citationCharacteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
Sepe, P., Ottini, A., Pircher, C. C., Franza, A., Claps, M., Guadalupi, V., Verzoni, E., & Procopio, G. (2021) · Cancers · doi:10.3390/cancers13153807 · Cited by 38
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
Smithy, J. W., Faleck, D. M., & Postow, M. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1240 · Cited by 39
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 41
Graham, J., Wells, J. C., Dudani, S., Gan, C. L., Donskov, F. N., Lee, J., Kollmannsberger, C., Meza, L., Beuselinck, B., Hansen, A. R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.002 · Cited by 36
Self-citationFacts and Hopes for Immunotherapy in Renal Cell Carcinoma
Yao, C., Zhang, T., Wu, T., & Brugarolas, J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2372 · Cited by 37
Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
Gan, L., Liu, D., Ma, Y., Chen, X., Dai, A., Zhao, S., Jin, X., & Gu, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.962596 · Cited by 39
“Furthermore, the ICI combination therapy can further activate the function of T cells and produce a synergistic anti-tumor effect compared to that of single-drug therapies (Motzer et al., 2018; Wang et al., 2018).”
BackgroundTracing Renal Cell Carcinomas back to the Nephron
Lindgren, D., Sjölund, J., & Axelson, H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.003 · Cited by 46
Jiang, A., Ye, J., Zhou, Y., Zhu, B., Lü, J., Ge, S., Qu, L., Xiao, J., Wang, L., & Cai, C. (2023) · Cells · doi:10.3390/cells12030349 · Cited by 37
Wolf, M. M., Rathmell, W. K., & de Cubas, A. A. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00700-5 · Cited by 39
Zibelman, M. R., Macfarlane, A. W., Costello, K., McGowan, T., O’Neill, J., Kokate, R. A., Borghaei, H., Denlinger, C. S., Dotan, E., Geynisman, D. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40028-z · Cited by 40
Self-citationAdvances in the management of renal cell carcinoma
Cardenas, L. M., Sigurdson, S. S., Wallis, C. J. D., Lalani, A. A., & Swaminath, A. (2024) · Canadian Medical Association Journal · doi:10.1503/cmaj.230356 · Cited by 34
“35 Most patients with immune-related adverse events will require systemic cortico steroids, such as prednisone 0.5–1 mg/kg taken orally, which should be managed in consultation with their oncologist.”
BackgroundInfluentialCracking the Codes behind Cancer Cells’ Immune Evasion
Mundhara, N., & Sadhukhan, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168899 · Cited by 41
“However, over 100 BsAbs targeting various solid malignancies have shown promising preclinical results and are currently being evaluated in clinical trials.”
BackgroundLee, C. H., Kang, M., Kwak, C. H., Ko, Y. H., Kim, J. K., Park, J. Y., Bang, S., Seo, S. I., Suh, J., Song, W., et al. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e293 · Cited by 34
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Amin, A., & Hammers, H. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03120 · Cited by 38
Self-citationJung, M., Ellinger, J., Gevensleben, H., Syring, I., Lüders, C., de Vos, L., Pützer, S., Bootz, F., Landsberg, J., Kristiansen, G., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.297549 · Cited by 36
Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Cimadamore, A., Liang Cheng, C., Antonio Lopez-beltran, B., Montironi, R., Pisconti, S., Battelli, N., et al. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00773-w · Cited by 34
Lü, J., Yang, J., Liang, Y., Meng, H., Zhao, J., & Zhang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01453 · Cited by 36
Therapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 35
Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival
Yang, Y., Shi, Z. Q., Bai, R., & Hu, W. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106609 · Cited by 36
Chanzá, N. M., Xie, W., Issa, M., Dzimitrowicz, H. E., Tripathi, A., Beuselinck, B., Lam, E. T., Zakharia, Y., McKay, R. R., Shah, S. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000538 · Cited by 35
Self-citationTakkenkamp, T. J., Jalving, M., Hoogwater, F. J. H., & Walenkamp, A. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0113 · Cited by 37
“…and bladder cancer, head and neck squamous-cell carcinoma, metastatic Merkel cell carcinoma, refractory classical Hodgkin lymphoma, microsatellite instability-high cancers (MSI), and gastric cancer (Emens et al. 2017, Wolchok et al. 2017, Motzer et al. 2018, Ward et al. 2018, Luchini et al. 2019).”
BackgroundIribe, Y., Furuya, M., Shibata, Y., Yasui, M., Funahashi, M., Ota, J., Iwashita, H., Nagashima, Y., Hasumi, H., Hayashi, N., et al. (2020) · Familial Cancer · doi:10.1007/s10689-020-00195-0 · Cited by 38
“The recent phase III trial CheckMate 214 involving patients with treatment-naïve intermediate- and poor-risk metastatic clear cell RCC (ccRCC) demonstrated that nivolumab plus ipilimumab improved overall survival (OS) and objective response rates (ORR) compared with sunitinib which is a tyrosine kinase inhibitor (TKI)…”
BackgroundThe Immunotherapy Landscape in Renal Cell Carcinoma
Brown, L. C., Desai, K. B., Zhang, T., & Ornstein, M. C. (2020) · BioDrugs · doi:10.1007/s40259-020-00449-4 · Cited by 37
Hermansen, C. K., & Donskov, F. N. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.12.008 · Cited by 37
Self-citationWang, Z., Guo, X., Gao, L., Wang, Y., Guo, Y. C., Xing, B., & Ma, W. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.12.012 · Cited by 38
Makino, T., Izumi, K., Hiratsuka, K., Kano, H., Shimada, T., Nakano, T., Kadomoto, S., Naito, R., Iwamoto, H., Yaegashi, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80302-4 · Cited by 35
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Roberto, M., Botticelli, A., Panebianco, M., Aschelter, A. M., Gelibter, A. J., Ciccarese, C., Minelli, M., Nuti, M., Santini, D., Laghi, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657639 · Cited by 39
“Nivolumab in combination with ipilimumab proved to be superior to sunitinib as the first-line therapy in the Phase III study Checkmate 214 (8).”
BackgroundInfluentialKim, H., Ahn, S., Kim, H.-S., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03781-6 · Cited by 37
Cure in metastatic breast cancer
Westphal, T., Gampenrieder, S. P., Rinnerthaler, G., & Greil, R. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0426-9 · Cited by 37
Immunotherapy in Urological Tumors.
Sharma, A., Suleyman, N. M., Jones, O., & Vasdev, N. (2019) · PubMed · Cited by 35
Understanding the Tumor Immune Microenvironment in Renal Cell Carcinoma
Shapiro, D. D., Dolan, B. K., Laklouk, I. A., Rassi, S., Ložar, T., Emamekhoo, H., Wentland, A. L., Lubner, M. G., & Abel, E. J. (2023) · Cancers · doi:10.3390/cancers15092500 · Cited by 40
“A phase II trial, IMmotion150, evaluated anti-PD-L1 therapy (atezolizumab) with or without an anti-VEGF antibody (bevacizumab) compared to the tyrosine kinase inhibitor, sunitinib.”
BackgroundInfluentialImmune checkpoint inhibitors and acute kidney injury
Zhou, P., Gao, Y., Kong, Z., Wang, J., Si, S., Han, W., Li, J., Lv, Z., & Wang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353339 · Cited by 40
Chrom, P., Żołnierek, J., Bodnar, L., Stec, R., & Szczylik, C. A. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-01390-x · Cited by 33
Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma
Xu, H., Xu, W., Ren, F., Wang, J., Wang, H., Cao, D., Shi, G., Qu, Y.-Y., Zhang, H., & Ye, D. (2020) · Aging · doi:10.18632/aging.102660 · Cited by 33
“Besides, since RCC patients respond to immunotherapy, immune checkpoint inhibitor [35, 36] also have been approved for advanced RCC patients.”
BackgroundImmune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma
Parikh, M., & Bajwa, P. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.009 · Cited by 38
“After demonstrating promising results in earlier phase studies, the Phase III CheckMate-214 trial was conducted, randomizing patients with treatment-naïve mRCC to receive either nivolumab plus ipilimumab or sunitinib, a tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF TKI), approved for first-line…”
ResultHultin, S., Nahar, K. J., Menzies, A. M., Long, G. V., Fernando, S. L., Atkinson, V. G., Cebon, J. S., & Wong, M. G. (2020) · BMC Nephrology · doi:10.1186/s12882-020-02044-9 · Cited by 35
Barth, D. A., Drulă, R., Ott, L. F., Fabris, L., Slabý, O., Călin, G. A., & Pichler, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00828 · Cited by 34
Kroeze, S. G. C., Fritz, C., Schaule, J., Siva, S., Kahl, K.-H., Sundahl, N., Blanck, O., Kaul, D., Adebahr, S., Verhoeff, J. J. C., et al. (2020) · British Journal of Urology · doi:10.1111/bju.15284 · Cited by 34
Yanase, T., Moritoki, Y., KONDO, H., Ueyama, D., Akita, H., & Yasui, T. (2020) · Urology Case Reports · doi:10.1016/j.eucr.2020.101508 · Cited by 38
Coen, O., Corrie, P. G., Marshall, H. C., Plummer, R., Ottensmeier, C. H. H., Hook, J., Bell, S., Sagoo, G. S., Meads, D. M., Bestall, J., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08509-w · Cited by 34
“Immune checkpoint inhibitors are now standard practice across multiple tumour sites including melanoma [4], lung [5], head and neck [6] and urological cancers [7,8].”
BackgroundCurrent cancer therapies and their influence on glucose control
Yim, C., Mansell, K. D., Hussein, N., & Arnason, T. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.1010 · Cited by 36
Brown, J. T., Liu, Y., Shabto, J. M., Martini, D. J., Ravindranathan, D., Hitron, E., Russler, G. A., Caulfield, S. E., Yantorni, L. B., Joshi, S. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002851 · Cited by 34
Demasure, S., Spriet, I., Debruyne, P. R., Laenen, A., Wynendaele, W., Baldewijns, M. M. L. L., Dumez, H., Clement, P. M., Wildiers, H. P. M. W., Schöffski, P., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1989720 · Cited by 38
Dai, X., Li, X., Liu, Y., & Yan, F. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110656 · Cited by 34
Favier, A., Varinot, J., Uzan, C., Duval, A., Brochériou, I., & Canlorbe, G. (2022) · Cancers · doi:10.3390/cancers14153783 · Cited by 37
On-Target Side Effects of Targeted Therapeutics of Cancer
Tímár, J., & Uhlyarik, A. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610694 · Cited by 38
Cai, Z., He, Y., Yu, Z.-Z., Hu, J., Xiao, Z., Zu, X., Li, Z., & Li, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933241 · Cited by 38
“The CheckMate 214 clinical trial has reported that intermediate-risk and poor-risk patients can benefit more from ICB treatment than targeted therapy (5).”
BackgroundNanomedicine for Combination Urologic Cancer Immunotherapy
Tian, Y., Liu, Z., Wang, J., Li, L., Wang, F., Zhu, Z. G., & Wang, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020546 · Cited by 33
“Treatment-related adverse events occurred in 93% of the nivolumab plus Ipilimumab group compared with 97% in the sunitinib group (NCT02231749) [19].”
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Nikoo, M., Rabiee, F., Mohebbi, H., Eghbalifard, N., Rajabi, H., Yazdani, Y., Sakhaei, D., Khosravifarsani, M., & Akhavan‐Sigari, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109881 · Cited by 35
Santoni, M., Massari, F., Myint, Z. W., Iacovelli, R., Pichler, M., Basso, U., Kopecký, J., Kucharz, J., Buti, S., Salfi, A., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.03.006 · Cited by 35
Self-citationTREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
Qiu, H., Shao, Z., Wen, X., Jiang, J., Ma, Q., Wang, Y., Huang, L., Ding, X., & Zhang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716710 · Cited by 32
“Over the past decade, tumor patients, especially those with advanced cancers witnessed the mushroom growth of cancer immunotherapies including oncolytic viruses, chimeric antigen receptor T cells, tumor vaccine and immune checkpoint inhibitors (ICIs) (2, 3), among them, ICIs were well on their way to becoming the most…”
BackgroundInfluentialThe clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis
Chen, D., & Wang, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106966 · Cited by 37
Multi-modal molecular programs regulate melanoma cell state
Andrews, M. C., Oba, J., Wu, C., Zhu, H., Karpinets, T. V., Creasy, C. A., Forget, M., Yu, X., Song, X., Mao, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31510-1 · Cited by 36
Choueiri, T. K., Powles, T. B., Voss, M. H., Plimack, E. R., Gurney, H., Song, Y., Perini, R. F., Rodriguez-Lopez, K., & Rini, B. I. (2023) · Future Oncology · doi:10.2217/fon-2023-0283 · Cited by 42
Self-citationWolf, M. M., Madden, M. Z., Arner, E. N., Bader, J. E., Ye, X., Vlach, L. M., Tigue, M. L., Landis, M. D., Jonker, P. B., Hatem, Z., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173934 · Cited by 37
“Combination ICB therapy (anti–CTLA-4 and anti–PD-1), along with antiangiogenics, is currently the first-line standard of care in metastatic ccRCC (11).”
BackgroundMethodImmune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 42
VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
Ndiaye, P. D., Dufies, M., Giuliano, S., Douguet, L., Grépin, R., Durivault, J., Lenormand, P., Glisse, N., Mintcheva, J., Vouret‐Craviari, V., et al. (2019) · Theranostics · doi:10.7150/thno.27794 · Cited by 38
“Immuno-therapies have also shown promising results in first-line treatment or after relapse on sunitinib [8, 9].”
ResultMonitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Zhang, M., Yang, H. J., Hua, W., Zhong, L., Xu, Z., & Qian, Q. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0678-0 · Cited by 38
Bex, A., Thienen, J. V., Schrier, M., Graafland, N. M., Kuusk, T., Hendricksen, K., Lagerveld, B. W., Zondervan, P. J., van Moorselaar, R. J. A., Blank, C. U., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0111 · Cited by 34
Adashek, J. J., Genovese, G., Tannir, N. M., & Msaouel, P. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100166 · Cited by 34
Self-citationLi, S., Sun, S., Xiang, H., Yang, J. L., Peng, M., & Gao, Q. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1746113 · Cited by 32
Westerdijk, K., Krens, S. D., van der Graaf, W. T. A., Mulder, S. F., van Herpen, C. M. L., Smilde, T. J., van Erp, N. P., & Desar, I. M. E. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14332 · Cited by 32
“The median (range) age was 62 (24-80) years and 77% of patients were male.”
BackgroundInfluentialMassari, F., Nunno, V. D., Guida, A., Silva, C. A. C., Derosa, L., Mollica, V., Colomba, É., Brandi, G., & Albiges, L. K. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.06.003 · Cited by 35
Chen, X., Yuan, S., Duan, J., Chen, Y.-M., Chen, S., Wang, Y., & Li, Y. (2020) · Disease Markers · doi:10.1155/2020/6717912 · Cited by 35
“All the 24 trials were conducted in metastatic or recurrent settings, among which twelve were performed in NSCLC [22, 23, 26, 28, 30, 32, 34, 36, 40–42, 44], five in melanoma [19, 25, 29, 35, 37], two in renal cell carcinoma [24, 38], two in gastric or gastroesophageal junction cancer [33, 39], one each in head and ne…”
BackgroundMethodKim, H., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kim, K., & Kim, S. T. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992992 · Cited by 34
Arias-Pinilla, G. A., & Modjtahedi, H. (2021) · Cancers · doi:10.3390/cancers13081781 · Cited by 35
Ikeda, T., Ishihara, H., Nemoto, Y., Tachibana, H., Fukuda, H., Yoshida, K., Takagi, T., Iizuka, J., Hashimoto, Y., Ishida, H., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.012 · Cited by 34
Yarza, R., Bover, M., Agulló-Ortuño, M. T., & Docampo, L. C. I. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02010-9 · Cited by 35
“To this matter, antibodies targeting the Programmed Death 1 (PD-1), such as pembrolizumab and nivolumab, others targeting Programmed Death Ligand 1 (PD-L1), atezolizumab, avelumab as well as the Cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) inhibiting antibody ipilimumab have demonstrated their effectiveness in…”
BackgroundPletcher, J. P., Bhattacharjee, S., Doan, J. P., Wynn, R. R., Sindhwani, P., Nadiminty, N., & Petros, F. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681441 · Cited by 33
“Hence, immune checkpoint inhibitors (CPIs), such as nivolumab, pembrolizumab, and ipilimumab, now constitute the mainstay of mRCC treatment (26, 27).”
BackgroundSelf-citationCombination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Rossi, E., Bersanelli, M., Gelibter, A. J., Borsellino, N., Caserta, C., Doni, L., Maruzzo, M., Mosca, A., Pisano, C., Verzoni, E., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01140-9 · Cited by 37
Branchoux, S., Sofeu, C. L., Gaudin, A.-F., Kurt, M., Moshyk, A., Italiano, A., Bellera, C. A., & Rondeau, V. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100340 · Cited by 32
“nivolumab (anti-programmed cell death protein 1) and ipilimumab (anti-Cytotoxic T-lymphocyte antigen-4).(2,3) In oncology, several clinical endpoints have been used to assess treatment efficacy.”
BackgroundVauchier, C., Auclin, É., Barthélémy, P., Carril-Ajuria, L., Ryckewaert, T., Borchiellini, D., Ajgal, Z. C., Bennamoun, M., Campedel, L., Thiery-Vuillemin, A., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3449660 · Cited by 32
“gov numbers: Checkmate025, NCT01668784 [3]; NIVOREN, NCT03013335; IMmotion150 NCT01984242; JAVELIN Solid Tumor, NCT01772004; JAVELIN Renal 101, NCT02684006 [6]; CLEAR, NCT02811861 [8]; Checkmate 214, NCT02231749 [4]; TiNivo, NCT03136627; and BIONIKK, NCT029609).”
BackgroundSelf-citationYekedüz, E., Tural, D. G., Ertürk, İ., Karakaya, S., Erol, C., Erçelep, Ö., Arslan, Ç., Sever, Ö. N., Kılıçkap, S., Öztaş, N. Ş., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04055-5 · Cited by 32
Liu, K., Zhao, S., Li, J., Zheng, Y., Wu, H., Kong, J., & Shen, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969217 · Cited by 34
“R. J. Motzer (2018) (21), R. J. Motzer (2019) (49) and D. F. McDermott (2018) (50) conducted significant trials of combination immunotherapy for RCC, and these studies confirmed that ICI-based combination therapy was more effective than sunitinib for RCC treatment.”
BackgroundInfluentialClinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 38
“Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), PD-1 and programmed death-ligand 1 (PD-L1) has revolutionized oncology due to their unprecedented levels of activity in tumors such as melanoma [99], non-small cell lung cancer [100,101], renal cell carcinoma [102], and…”
BackgroundA novel chemokine‐based signature for prediction of prognosis and therapeutic response in glioma
Fan, W., Wang, D., Li, G., Xu, J., Ren, C., Sun, Z., Wang, Z., Ma, W., Zhao, Z., Bao, Z., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13944 · Cited by 37
Immune-based combination therapy for esophageal cancer
Wang, H., Xu, Y., Zuo, F., Liu, J., & Yang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020290 · Cited by 35
Atkins, M. B., Jegede, O. A., Haas, N. B., McDermott, D. F., Bilen, M. A., Stein, M. N., Sosman, J. A., Alter, R. S., Plimack, E. R., Ornstein, M. C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004780 · Cited by 34
Self-citationSomatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing
Wang, J., Xi, Z., Xi, J., Zhang, H., Li, J., Xia, Y., & Yi, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0661-5 · Cited by 33
Retz, M. M., Bedke, J., Bögemann, M., Grimm, M., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M. P., Bolenz, C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.001 · Cited by 32
Self-citationDougan, M. L. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-0752-z · Cited by 36
CheckMate-067: Raising the Bar for the Next Decade in Oncology
Weiss, S. A., & Kluger, H. M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02549 · Cited by 34
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
Albiges, L., Bourlon, M. T., Chacón, M., Cutuli, H. J., Chuken, Y. A. L., Żurawski, B., Mota, J. M., Magri, I., Burotto, M., Luz, M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.002 · Cited by 31
Self-citation
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.